You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》交銀國際升康方生物(09926.HK)目標價至67元 卡度尼利胃癌sNDA獲受理
交銀國際發表報告指,康方生物(09926.HK)的卡度尼利胃癌sNDA獲受理,相關數據未來將於學術會議或學術期刊上發表,無論PD-L1表達如何,卡度尼利在整體晚期胃癌中展示出高效的腫瘤緩解和生存獲益。 交銀國際表示,進入今年上半年,國內III期AK102-303試驗即將迎來重要數據讀出。該行認為,該臨床結果將一定程度上影響市場對於產品海外臨床研究結果和長期出海前景的預期;根據II期結果,預計303試驗的成功可能性較大。 交銀國際續指,基於近期臨床數據更新和NDA提交,將卡度尼利的一線胃癌POS上調至90%,經POS調整高峰產品銷售預測上調至52億元人民幣。同時,考慮到派安普利單抗的轉產安排,將公司在2023年至25年銷售收入預測下調,故公司在2023年至25年各年收入預測分別下調3%、0.2%、5%,惟將2027年後的收入預測上升3%至11%。該行將其目標價由57元上調至67元,維持其評級為「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account